Delving into the Latest Updates on Yuxi Walvax Biotechnology Co., Ltd. with Synapse

Overview

Tags

Infectious Diseases

Other Diseases

Nervous System Diseases

Prophylactic vaccine

Conjugated vaccine

Combination vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	7
Nervous System Diseases	2

Top 5 Drug Type	Count

Prophylactic vaccine	7
Conjugated vaccine	3
Combination vaccine	1

Primary study objective: To evaluate the safety of adsorbed acellular diphtheria, tetanus and pertussis/Haemophilus influenzae type b combined vaccine in healthy people aged 3 months and above. Secondary study objective: To preliminarily evaluate the immunogenicity of 3-month-old healthy people after 3 doses of adsorbed acellular diphtheria, tetanus and pertussis/Haemophilus influenzae type b combined vaccine.

Start Date15 Dec 2023

Sponsor / Collaborator

Yuxi Walvax Biotechnology Co., Ltd.

[+1]

CTR20220983 / CompletedPhase 4

采用随机、双盲、试验疫苗不同批次间相互对照的设计，比较和评价三个连续生产批次试验疫苗间的免疫原性和安全性的批间一致性。

[Translation] A randomized, double-blind, cross-comparison design was used to compare and evaluate the batch consistency of immunogenicity and safety among three consecutive production batches of the test vaccine.

通过考察2~5岁健康儿童接种不同批次13价肺炎球菌多糖结合疫苗后的免疫原性和安全性，比较和评价三个连续生产批次试验疫苗间的批间一致性。

[Translation]

The immunogenicity and safety of different batches of 13-valent pneumococcal polysaccharide conjugate vaccine were investigated in healthy children aged 2 to 5 years, and the batch consistency of the test vaccine among three consecutive production batches was compared and evaluated.

Start Date21 Sep 2022

Sponsor / Collaborator

Yuxi Walvax Biotechnology Co., Ltd.

[+1]

CTR20220707 / CompletedPhase 4

采用单中心、随机、开放性的非劣效试验设计，评价13价肺炎球菌多糖结合疫苗与吸附无细胞百白破联合疫苗同时接种或间隔接种的免疫原性和安全性临床研究

[Translation] A single-center, randomized, open-label, non-inferiority trial was designed to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide conjugate vaccine and adsorbed acellular diphtheria, tetanus and pertussis combined vaccine administered simultaneously or at intervals.

评价13价肺炎球菌多糖结合疫苗在3月龄健康婴儿中和免疫规划吸附无细胞百白破联合疫苗同时接种或间隔接种的免疫原性和安全性。

[Translation]

To evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide conjugate vaccine administered simultaneously or at intervals with adsorbed acellular diphtheria, tetanus and pertussis combined vaccine in immunization schedule in healthy infants aged 3 months.

Start Date14 May 2022

Sponsor / Collaborator

Yuxi Walvax Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with Yuxi Walvax Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Yuxi Walvax Biotechnology Co., Ltd.

Login to view more data

4

Literatures (Medical) associated with Yuxi Walvax Biotechnology Co., Ltd.

06 Nov 2022·Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

[The surveillance analysis of the adverse events following immunization of the domestic 13-valent pneumococcal polysaccharide conjugate vaccine in Zhejiang Province].

Article

Author: Yang, S Y ; Yan, X M ; Chen, J J ; Pan, X J ; Wang, Y ; Huang, Z ; Hu, Y ; Chen, Y P ; Chen, Y Y ; Liang, H ; Yuan, L ; Lyu, H K ; Qin, X ; Tao, Q

To evaluate the safety of the domestic 13-valent pneumococcal polysaccharide conjugate vaccine-tetanus toxoid protein (PCV13-TT) after its licensure. The adverse event following immunization (AEFI) and the vaccination data of PCV13-TT in Zhejiang province from July 2020 to October 2021 were collected from national adverse event following immunization surveillance system and Zhejiang provincial immunization information system. Descriptive epidemiological method was used for this analysis. From July 2020 to October 2021, 302 317 doses of PCV13-TT were administered in children under 6 years old in Zhejiang Province and 636 AEFI case reports were received, with a reporting rate of 21.04 per 10 000 doses. Of these AEFI cases, 97.17% were mild vaccine product-related reaction (20.54 per 10 000 doses) and 95.44% occurred in the 0-1 d after vaccination (20.08 per 10 000 doses). The most common clinical diagnoses of AEFI included fever (224 cases), redness (204 cases), and induration (190 cases), while allergic rash (11 cases) was the most common diagnosis among the abnormal reactions. In conclusion,the present results bolstered that the domestic PCV13-TT was generally well tolerated in children under 6 years old in Zhejiang Province.

Organic Chemistry Frontiers

Synthesis and immunogenicity evaluation of oligosaccharide epitopes for the development of a glycoconjugate vaccine against Streptococcus pneumoniae serotype 3

Author: Gu, Guofeng ; Wang, Guirong ; Chen, Jiaxin ; Huang, Zhen ; Zhao, Jielin ; Ma, Xiaolin ; Li, Jiaqi

A preliminary structure–activity relationship study revealed the potential ST3 oligosaccharide antigenic epitope for anti-ST3 vaccine development.

Zhongguo Shengwu Zhipinxue Zazhi

Evaluation on stability of Haemophilus influenzae type b conjugate vaccine

Author: Wu, Xiu-li ; Ma, Bo ; Huang, Zhen ; Xu, Dong-mei ; Yang, Li ; Qian, Wen ; Fang, Guo-liang ; Li, Zi-cai

Objective To evaluate the stability of Haemophilus influenza type b (Hib)conjugate vaccine stored at 2-8°C.Methods A total of 11 batches of Hib conjugate vaccine put on the market after lot release, manufactured by Yuxi Walvax Biotechnol. Co. , Ltd., were stored at 2-8°C, from which samples were taken at months 0, 3, 6, 9, 12, 18, 24 and 30 after storage for identity test, inspection on final containers, determinations of polysaccharide content, pH value, sodium chloride content, high mol. conjugate content and polysaccharide mol. size, potency test, sterility test, pyrogen test, abnormal toxicity test and bacterial endotoxin test to evaluate the stability.Results All the indexes of Hib conjugate vaccine met the quality standard 30 mo after storage at 2-8°C.Conclusion Hib conjugate vaccine showed high stability after storage at 2-8°C for 30 mo.

100 Deals associated with Yuxi Walvax Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Yuxi Walvax Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

6

Approved

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Haemophilus Influenzae Type b Conjugate Vaccine(Yuxi Walvax Biotechnology Co., Ltd.)	Haemophilus Infections More	Approved
Meningococcal Group A, C Bivalent Polysaccharide Conjugate Vaccine(Walvax Biotechnology Co., Ltd.)	Meningitis, Meningococcal More	Approved
Diphtheria,tetanus and acellular pertussis combined Vaccine,adsorbed(Yuxi Walvax Biotechnology Co., Ltd.)	Diphtheria More	Approved
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Walvax Biotechnology)	Pneumococcal Infections More	Approved
Pneumococcal polysaccharide vaccine 23-valent (Walvax Biotechnology)	Pneumococcal Infections More	Approved